Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACLY | P53396 | 6/20 | 0.56 |
| ▸ | SUCNR1 | Q9BXA5 | 1/20 | 0.48 |
| ▸ | HDAC1 | Q13547 | 6/20 | 0.48 |
| ▸ | DHODH | Q02127 | 1/20 | 0.48 |
| ▸ | STING1 | Q86WV6 | 1/20 | 0.45 |
| ▸ | HDAC2 | Q92769 | 3/20 | 0.44 |
| ▸ | SERPINE1 | P05121 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 2/20 | 0.43 |
| ▸ | MEN1 | O00255 | 1/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.43 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.43 |
| ▸ | GSK3B | P49841 | 1/20 | 0.43 |
| ▸ | PRSS12 | P56730 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2269782 | 0.84 | ACLY (0.56) | ACLYSUCNR1HDAC1DHODHSTING1 | |
| SCHEMBL2270071 | 0.84 | SERPINE1 (0.46) | STING1SERPINE1PRSS12 | |
| SCHEMBL2268313 | 0.84 | KDM5A (0.47) | STING1MEN1PKMKMT2A | |
| SCHEMBL1316866 | 0.82 | ACLY (0.62) | ACLYSUCNR1HDAC1DHODHHDAC2 | |
| SCHEMBL2269037 | 0.81 | ACLY (0.59) | ACLYSUCNR1HDAC1DHODHHDAC2 | |
| SCHEMBL2272006 | 0.80 | ACLY (0.62) | ACLYSUCNR1HDAC1DHODHHDAC2 | |
| SCHEMBL2272853 | 0.79 | ACLY (0.60) | ACLYSUCNR1HDAC1DHODHHDAC2 | |
| SCHEMBL28767708 | 0.78 | LMNA (0.57) | HDAC1HDAC2MEN1KMT2A | |
| SCHEMBL2275720 | 0.78 | SUCNR1 (0.73) | ACLYSUCNR1HDAC1DHODHHDAC2 | |
| SCHEMBL2274895 | 0.78 | ACLY (0.56) | ACLYSUCNR1HDAC1DHODHHDAC2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7999132-B2 | Anthranilic acid derivative or salt thereof | TOYAMA CHEMICAL CO., LTD. (JP) | 2011-08-16 | — | — | US | disclosed |
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2009-09-24 | — | — | US | disclosed |
| EP-1820795-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | TOYAMA CHEMICAL CO., LTD. (JP) | 2007-08-22 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20090240052-A1 | NOVEL ANTHRANILIC ACID DERIVATIVE OR SALT THEREOF | MMP13, MMP26, MMP11 | ACLY 653/4885SUCNR1 637/4885HDAC1 71/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.